Caroline Lefeuvre1, Adeline Pivert2, Hélène Le Guillou-Guillemette2, Françoise Lunel-Fabiani2, Pascal Veillon2, Anne-Sophie Le Duc-Banaszuk3, Alexandra Ducancelle2. 1. CHU d'Angers, Laboratoire de Virologie et Laboratoire HIFIH, UPRES EA 3859, 4, rue Larrey, 49 000, Angers, France. Electronic address: caroline.lefeuvre@chu-angers.fr. 2. CHU d'Angers, Laboratoire de Virologie et Laboratoire HIFIH, UPRES EA 3859, 4, rue Larrey, 49 000, Angers, France. 3. Centre Régional de Coordination des Dépistages des Cancers Pays de la Loire (CRCDC), Structure de Gestion des Cancers, 5 rue des Basses Fouassières, 49 100, Angers, France.
Abstract
OBJECTIVES: In France, cervical cancer screening is based on human papillomavirus (HPV) testing on cervical samples (women aged 30-65) and cytological examination of Pap smears (25-29), but screening coverage is unsatisfactory. The CapU3 study aimed to propose urinary HPV testing on 13,535 women aged 35 to 65 who had not had a Pap smear since 2010. METHODS: High-risk HPV (HR-HPV) detection was performed using a real-time PCR (Anyplex II HPV 28 Detection, Seegene®). Women with HR-HPV positive results were encouraged to have a cervical smear as soon as possible to detect the presence of cervical lesions. RESULTS: The participation rate was 15.4%. Out of the 1,915 analyzed specimens, 1,711 and 190 were negative and positive, respectively, for at least 1 HR-HPV genotype. HR-HPV genotypes other than HPV-16 or HPV-18 were mostly detected as HPV-53 (23.7%) and HPV-68 (14.2%). A satisfactory gynecological follow-up was observed for HPV-positive women (92.1%). 23 abnormal smears were observed and eight high-grade cytological lesions after colposcopy and biopsy were diagnosed. CONCLUSIONS: As home HPV urinary testing is non-invasive and does not require medical attention, this method may be an alternative for women who are reluctant to have a Pap smear and thus extend screening coverage.
OBJECTIVES: In France, cervical cancer screening is based on human papillomavirus (HPV) testing on cervical samples (women aged 30-65) and cytological examination of Pap smears (25-29), but screening coverage is unsatisfactory. The CapU3 study aimed to propose urinary HPV testing on 13,535 women aged 35 to 65 who had not had a Pap smear since 2010. METHODS: High-risk HPV (HR-HPV) detection was performed using a real-time PCR (Anyplex II HPV 28 Detection, Seegene®). Women with HR-HPV positive results were encouraged to have a cervical smear as soon as possible to detect the presence of cervical lesions. RESULTS: The participation rate was 15.4%. Out of the 1,915 analyzed specimens, 1,711 and 190 were negative and positive, respectively, for at least 1 HR-HPV genotype. HR-HPV genotypes other than HPV-16 or HPV-18 were mostly detected as HPV-53 (23.7%) and HPV-68 (14.2%). A satisfactory gynecological follow-up was observed for HPV-positive women (92.1%). 23 abnormal smears were observed and eight high-grade cytological lesions after colposcopy and biopsy were diagnosed. CONCLUSIONS: As home HPV urinary testing is non-invasive and does not require medical attention, this method may be an alternative for women who are reluctant to have a Pap smear and thus extend screening coverage.
Authors: Celine Audiger; Thomas Bovagnet; Julia Bardes; Gaelle Abihsera; Jerome Nicolet; Michel Deghaye; Audrey Bochaton; Gwenn Menvielle Journal: Int J Public Health Date: 2022-07-04 Impact factor: 5.100
Authors: Mirte Schaafsma; Rianne van den Helder; Maaike C G Bleeker; Fleur Rosier-van Dunné; Irene A M van der Avoort; Renske D M Steenbergen; Nienke E van Trommel Journal: Prev Med Rep Date: 2022-02-28
Authors: Caroline Lefeuvre; Hélène De Pauw; Anne-Sophie Le Duc Banaszuk; Adeline Pivert; Alexandra Ducancelle; Franck Rexand-Galais; Marc Arbyn Journal: Int J Public Health Date: 2022-02-24 Impact factor: 3.380
Authors: Francisco I Torres-Rojas; Miguel A Mendoza-Catalán; Luz Del C Alarcón-Romero; Isela Parra-Rojas; Sergio Paredes-Solís; Marco A Leyva-Vázquez; Jair E Cortes-Arciniega; Carlos J Bracamontes-Benítez; Berenice Illades-Aguiar Journal: PeerJ Date: 2021-06-17 Impact factor: 2.984